Technology for assessing the efficiency of human cell transfection with the gene therapy drug GT-DCN-AAV-DJ-01 and the level of DCN transgene expression in vitro during preclinical studies of the drug for the treatment of epidermolysis bullosa
RU2024140289A3Pending Publication Date: 2026-06-30FEDERALNOE GOSUDARSTVENNOE BYUDZHETNOE UCHREZHDENIE NATSIONALNYJ MEDITSINSKIJ ISSLEDOVATELSKIJ TSENTR AKUSHERSTVA GINEKOLOGII I PERINATOLOGII IMENI AKADKA V I KULAKOVA MINISTSTVA ZDRAVOOKHRANENIYA ROSSIJSKOJ FEDERATSII
View PDF 0 Cites 0 Cited by
Patent Information
- Authority / Receiving Office
- RU · RU
- Patent Type
- Applications
- Current Assignee / Owner
- FEDERALNOE GOSUDARSTVENNOE BYUDZHETNOE UCHREZHDENIE NATSIONALNYJ MEDITSINSKIJ ISSLEDOVATELSKIJ TSENTR AKUSHERSTVA GINEKOLOGII I PERINATOLOGII IMENI AKADKA V I KULAKOVA MINISTSTVA ZDRAVOOKHRANENIYA ROSSIJSKOJ FEDERATSII
- Filing Date
- 2024-12-28
- Publication Date
- 2026-06-30
Abstract
Technology for assessing the efficiency of transfection of human cells with the gene therapy drug GT-DCN-AAV-DJ-01 and the level of expression of the DCN transgene in vitro during preclinical studies of the drug for the treatment of epidermolysis bullosa in the test sample by performing PCR using a forward primer having the sequence SEQ ID NO: 1 and a reverse primer having the sequence SEQ ID NO: 2.
Need to check novelty before this filing date? Find Prior Art